FDA's pediatric rules could mean more CRO work

The FDA is adding teeth to rules requiring some drugmakers to conduct pediatric trials of new therapies, and the toughened enforcement could create an opportunity for CROs, Outsourcing-Pharma reports. The agency has decided to start posting noncompliance letters online, putting violators in the spotlight and, as an analyst told the website, this may spur drugmakers to reach out to CROs and get trials rolling to ward off FDA scorn. Article

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.